NO20076389L - Compositions and methods for treating HIV infection with cupredoxin and cytochrome C - Google Patents

Compositions and methods for treating HIV infection with cupredoxin and cytochrome C

Info

Publication number
NO20076389L
NO20076389L NO20076389A NO20076389A NO20076389L NO 20076389 L NO20076389 L NO 20076389L NO 20076389 A NO20076389 A NO 20076389A NO 20076389 A NO20076389 A NO 20076389A NO 20076389 L NO20076389 L NO 20076389L
Authority
NO
Norway
Prior art keywords
cupredoxin
cytochrome
infection
methods
compositions
Prior art date
Application number
NO20076389A
Other languages
Norwegian (no)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Arsenio Fialho
Anita Chaudhari
Chang Soo Hong
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20076389L publication Critical patent/NO20076389L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Sammendrag Den foreliggende oppfinnelsen er relatert til kupredoksin, spesifikt Pseudomonas aeruginosa azurin og/eller Pseudomonas aeruginosa cytokrom C551 og deres anvendelse i inhibering av viral infeksjon, og spesielt infeksjon av mammalske celler ved det humane immunsvikt viruset (HIV). Oppfinnelsen er også relatert til varianter og derivater av kupredoksin og cytokrom c som beholder evnen til å inhibere viral infeksjon, og spesielt infeksjon ved det humane immunsvikt viruset (HIV). Oppfinnelsen er også relatert til forskningsmetoder for å studere viral og bakteriell infeksjon i mammalske celler.Summary The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurine and / or Pseudomonas aeruginosa cytochrome C551 and their use in inhibiting viral infection, and in particular, infection of mammalian cells by the human immunodeficiency virus (HIV). The invention is also related to variants and derivatives of cupredoxin and cytochrome c which retain the ability to inhibit viral infection, and in particular infection by the human immunodeficiency virus (HIV). The invention is also related to research methods for studying viral and bacterial infection in mammalian cells.

NO20076389A 2005-05-20 2007-12-11 Compositions and methods for treating HIV infection with cupredoxin and cytochrome C NO20076389L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68283305P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US78086806P 2006-03-10 2006-03-10
PCT/US2006/019565 WO2006127514A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c

Publications (1)

Publication Number Publication Date
NO20076389L true NO20076389L (en) 2008-02-20

Family

ID=37452656

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076389A NO20076389L (en) 2005-05-20 2007-12-11 Compositions and methods for treating HIV infection with cupredoxin and cytochrome C

Country Status (10)

Country Link
EP (1) EP1883650A4 (en)
JP (1) JP2008545398A (en)
KR (1) KR20080024124A (en)
AU (1) AU2006251644A1 (en)
BR (1) BRPI0612431A2 (en)
CA (1) CA2608398A1 (en)
IL (1) IL187160A0 (en)
MX (1) MX2007014599A (en)
NO (1) NO20076389L (en)
WO (1) WO2006127514A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
JP2009502797A (en) * 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for controlling angiogenesis with cupredoxins
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
AU2007329375A1 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411963A4 (en) * 2001-02-15 2005-01-19 Univ Illinois Cytotoxic factors for modulating cell death
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CA2607739A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome

Also Published As

Publication number Publication date
KR20080024124A (en) 2008-03-17
IL187160A0 (en) 2008-02-09
CA2608398A1 (en) 2006-11-30
EP1883650A2 (en) 2008-02-06
WO2006127514A2 (en) 2006-11-30
EP1883650A4 (en) 2009-06-10
JP2008545398A (en) 2008-12-18
MX2007014599A (en) 2008-02-07
WO2006127514A3 (en) 2008-06-26
BRPI0612431A2 (en) 2009-02-10
AU2006251644A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2003079757A3 (en) Hiv therapeutic
NO20070487L (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors.
BRPI0514176A (en) hcv replication inhibitors
NO20073105L (en) pyridazinone
WO2009106019A3 (en) Chemical compounds having antiviral activity against dengue virus and other flaviviruses
MA33209B1 (en) INHIBITORS OF HEPATITIS C VIRUS REPLICATION
WO2007095269A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2008085508A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
NO20085176L (en) Phenyl substituted heteroaryl derivatives and use as anti-tumor agents
NO20076059L (en) 2,4-Diamino-pyrimidines used as aurora inhibitors
BRPI0511834A (en) methods for treating hepatitis c
TNSN07066A1 (en) RNA DEPENDENT RNA-POLYMERASE INHIBITORS, HEPATITIS C VIRUS, AND COMPOSITIONS AND TREATMENTS USING SAME
CY1114356T1 (en) SUSPENSION VIRUS INHIBITIONS C
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
WO2008061208A3 (en) Arylsulfonamide compounds
NO20071366L (en) Chemical connections
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2004037784A3 (en) Pyrrolidones with anti-hiv activity
ATE494291T1 (en) COMPOUNDS FOR TREATING HEPATITIS C
NO20082862L (en) Novel alkylphospholipid derivatives with reduced cytotoxicity and use thereof
NO20076391L (en) Compositions and methods for treating states related to efrine signals with cupredoxin
ATE505473T1 (en) CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
NO20076389L (en) Compositions and methods for treating HIV infection with cupredoxin and cytochrome C

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application